Publication & Citation Trends
Most Cited Works
Publications
79 total
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.
Cited by 1
Semantic Scholar
Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.
Cited by 5
Semantic Scholar
EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas
Cited by 1
Semantic Scholar
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial PDF
Cited by 1,160
OpenAlex
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 PDF
Cited by 261
OpenAlex
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Cited by 354
OpenAlex
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331 PDF
Cited by 103
OpenAlex
Research Topics
Hepatocellular Carcinoma Treatment and Prognosis
(19)
Advanced MRI Techniques and Applications
(17)
Cancer Immunotherapy and Biomarkers
(15)
Lung Cancer Treatments and Mutations
(14)
MRI in cancer diagnosis
(13)
Frequent Co-Authors
Affiliations
Northwestern University
University of Iowa
Janssen (Belgium)
Inserm
Bristol-Myers Squibb (Germany)